Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Our Therapies
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jess Rowlands

    Head of Corporate Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

  • Read more about bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference

  • Read more about bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference

bluebird bio at 40th Annual J.P. Morgan Healthcare Conference

  • Read more about bluebird bio at 40th Annual J.P. Morgan Healthcare Conference

bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

  • Read more about bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

  • Read more about bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

  • Read more about bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM

  • Read more about New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM

New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels

  • Read more about New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels

bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions

  • Read more about bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions

bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress

  • Read more about bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Current page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2023 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

Live - Social Links